Evidence map›Paper›PMID 33631053›Full record

ArticleCancer2021

Trends and racial disparities in aggressive end-of-life care for a national sample of women with ovarian cancer.

Megan A Mullins, Julie J Ruterbusch, Philippa Clarke, Shitanshu Uppal, Lauren P Wallner, Michele L Cote

Abstract read
In one paragraph

Article in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. You Get (offered) What You (can) Pay for: Explaining Disparities in End-of-Life Cancer Care.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  11. Trends in hospice referral timing and location among individuals dying of ovarian cancer: persistence of missed opportunities.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023
    Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Megan A MullinsCenter for Improving Patient and Population Health and Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-2753-9068
Julie J RuterbuschWayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan.
Philippa ClarkeDepartment of Epidemiology and Institute for Social Research, University of Michigan, Ann Arbor, Michigan.
Shitanshu UppalDepartment of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan.
Lauren P WallnerDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Michele L CoteWayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan.

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Interdisciplinary Research Training Center in Cancer Care DeliveryT32CA236621 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Lauren P Wallner · 2020 to 2026
$2.8M
NCI NIH HHS P30 CA046592NCI NIH HHS T32 CA236621
6 · The paper itself

Abstract

backgroundThe clinical landscape has moved toward less aggressive end-of-life care for women with ovarian cancer. However, whether there has been a decline in the use of aggressive end-of-life services is unknown. The authors evaluated current national trends and racial disparities in end-of-life care among women with ovarian cancer using the Surveillance, Epidemiology, and End Results-Medicare-linked data set.

methodsIn total, 7756 Medicare beneficiaries aged >66 years with ovarian cancer who died between 2007 and 2016 were identified. The authors examined trends and racial disparities in late hospice or no hospice use, >1 emergency department (ED) visit, intensive care unit admission, >1 hospitalization, terminal hospitalization, chemotherapy, and invasive and/or life-extending procedures using multivariable logistic regression.

resultsThe median hospice length of stay did not change over time; however, women were increasingly admitted to the intensive care unit and had multiple ED visits in the last month of life (P < .001). Not enrolling in hospice at the end of life and terminal hospitalizations decreased over time (P < .001). Non-White women were more likely to receive aggressive end-of-life care, particularly for hospital-related utilization and life-extending procedures, whereas non-Hispanic Black women were more likely to have >1 ED visit (odds ratio, 2.04; 95% CI, 1.57-2.64) or life-extending procedures (odds ratio, 1.89; 95% CI, 1.45-2.48) compared with non-Hispanic White women.

conclusionsDespite clinical guidelines and increasing emphasis on reducing aggressive end-of-life care, the use of aggressive end-of-life care for women with ovarian cancer persists, and care is most aggressive for non-White women.

Indexed as

Hospice CareHospicesOvarian NeoplasmsTerminal CareAgedFemaleHospitalizationHumansMedicareUnited Stateshospice careovarian cancerracial disparityterminal care

Identifiers

PMID33631053
PMCPMC8195844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.